-
Mashup Score: 9
Aotearoa, New Zealand had a mandatory adalimumab biosimilar transition from March – September 2022. A survey reveals low satisfaction with biosimilar’s quality, as well as the lack of alcoholic wipes and a support program.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 10Broadcast - 6 month(s) ago
Developed under the direction and sponsorship of Fresenius Kabi. Virtual Broadcast: Adopting Biosimilars in Immunology Practice: A Panel DiscussionAbstract: This nationally broadcast panel discussion is focused on the current immunology biosimilar landscape and value of biosimilars for patients and…
Source: events.medscape.comCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 0Low-Flexibility Insurance Plans More Likely to Prescribe Biosimilars - 6 month(s) ago
Results revealed the health plan type highly influenced the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0Low-Flexibility Insurance Plans More Likely to Prescribe Biosimilars - 6 month(s) ago
Results revealed the health plan type highly influenced the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0FDA Approves Interchangeable Biosimilar to Ustekinumab - 6 month(s) ago
The FDA announced the approval of ustekinumab-auub (Wezlana) as a biosimilar and interchangeable to ustekinumab (Stelara) for a half dozen inflammatory conditions on October 31, 2023.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Rheumatoid Arthritis Quiz: Understanding Biosimilars in RA - 6 month(s) ago
The number of biosimilars in rheumatology is growing. Test your knowledge of biosimilars with this quiz.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1Rheumatoid Arthritis Quiz: Understanding Biosimilars in RA - 6 month(s) ago
The number of biosimilars in rheumatology is growing. Test your knowledge of biosimilars with this quiz.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0No Differences in Safety, Immunogenicity Observed in Patients Switching to Biosimilar - 7 month(s) ago
Results of a recent systematic review demonstrated no difference in the immunogenicity rates and safety profiles in patients who switched to a biosimilar and those who continued to receive the reference product.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0Providers Express Difficulties in Transitioning to Biosimilars - 7 month(s) ago
Providers identified an increased administrative workload and inadequate biosimilar device training as pain points during a mandatory switch to a biosimilar.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Providers Express Difficulties in Transitioning to Biosimilars - 7 month(s) ago
Providers identified an increased administrative workload and inadequate biosimilar device training as pain points during a mandatory switch to a biosimilar.
Source: www.hcplive.comCategories: Latest Headlines, RheumatologyTweet
A study, led by @ChiaraG__ @AucklandUni, sent out a survey to patients who went through a mandated adalimumab #biosimilar transition in Aotearoa, New Zealand. Patients expressed low satisfaction with the transition. https://t.co/ISvuRTohtb https://t.co/GUQhmYWjQZ